MedTrace Logo

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

NCT05434156 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2025-02-19

No results posted yet for this study

Summary

A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).

Conditions

Interventions

DRUG

ELE-101

ELE-101 solution for intravenous infusion

DRUG

ELE-101 Placebo

ELE-101 placebo matching solution for intravenous infusion

Sponsors & Collaborators

  • Beckley Psytech Limited

    collaborator INDUSTRY

  • Eleusis Therapeutics

    lead INDUSTRY

Principal Investigators

  • Neel Bhatt · MAC Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-27
Primary Completion
2025-12-31
Completion
2026-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05434156 on ClinicalTrials.gov